NEU
NEUREN PHARMACEUT. ORDINARYNeuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide) for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 clinical trial for the treatment of Phelan-McDermid; and in Phase 2 clinical trial for the treatment of Angelman and Pitt Hopkins. In addition, it develops NNZ-2591, which is in preclinical trial stage for the treatment of Prader-Willi syndrome, Hypoxic Ischemic Encephalopathy, and SYNGAP1. The company was incorporated in 2001 and is based in Hawthorn East, Australia.
NEU
NEU
NEUREN PHARMACEUT. ORDINARY
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide) for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome.
Fundamentals
Historical Data63 days
| Date | Short % | Gross Short |
|---|---|---|
| 16 July | — | — |
| 15 July | — | — |
| 14 July | — | — |
| 13 July | 4.72% | — |
| 10 July | 4.78% | — |
| 9 July | 4.86% | — |
| 8 July | 4.91% | — |
| 7 July | 4.90% | — |
| 6 July | 4.95% | — |
| 3 July | 4.96% | — |
| 2 July | 4.96% | — |
| 1 July | 5.02% | — |
Neuren Pharmaceut (NEU) Short Interest Summary
Neuren Pharmaceut (NEU) currently has 4.72% of its shares sold short (6.0 million shares, worth approximately $104.7 million), based on ASIC short position data reported on 13 July 2026 (T+4 reporting lag). That makes NEU the #68 most shorted stock on the ASX most shorted list. Short interest in NEU is down 0.23% over the past week and down 1.68% over the past month. NEU is part of the Health Care sector on the ASX.
Recent NEU Short Position History
| Date | Short % | Short Shares | Close Price |
|---|---|---|---|
| 13 July 2026 | 4.72% | 6.0M | $16.50 |
| 10 July 2026 | 4.78% | 6.1M | $16.52 |
| 9 July 2026 | 4.86% | 6.2M | $16.78 |
| 8 July 2026 | 4.91% | 6.2M | $16.74 |
| 7 July 2026 | 4.90% | 6.2M | $16.34 |
| 6 July 2026 | 4.95% | 6.3M | $16.65 |
| 3 July 2026 | 4.96% | 6.3M | $16.74 |
| 2 July 2026 | 4.96% | 6.3M | $17.00 |
| 1 July 2026 | 5.02% | 6.4M | $17.65 |
| 30 June 2026 | 5.19% | 6.6M | $17.75 |
NEU Short Selling — Frequently Asked Questions
What is Neuren Pharmaceut (NEU)'s current short interest?
Neuren Pharmaceut (NEU) currently has a short interest of 4.72% of total shares outstanding. This means 4.72% of NEU's shares have been sold short by investors who expect the price to decline. This data is sourced from ASIC reports and updated daily.
Is NEU heavily shorted on the ASX?
NEU has a relatively low short interest of 4.72%. Short interest below 5% generally suggests limited bearish sentiment from short sellers.
What does short interest mean for NEU investors?
Short interest in NEU shows the percentage of shares investors have borrowed and sold, betting the price will fall. At 4.72%, NEU's short interest is at a low level. See our short squeeze candidates and days to cover analysis for more context.
Where does this NEU short data come from?
Short position data is published by ASIC with a four trading day delay (T+4) and covers reported short positions as a percentage of total shares on issue. ASX Short Data also tracks daily gross short sales (T+1), securities lending, and director trades for NEU.